Table 6.

Adverse Events Reported in More Than 3% of Patients From Baseline to 1 Year

Adverse Event	Risedronate (n = 106)						Placebo (n = 106)						P
	Grade 1/2		Grade 3		Grade 4		Grade 1/2		Grade 3		Grade 4
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Arthralgia	0	0	0	0	0	0	1	1	3	3	0	0	.045
Chest pain	0	0	0	0	0	0	2	2	2	2	0	0	.045
Constipation	52	49	1	1	0	0	61	58	0	0	0	0	.19
Headache	40	37	2	2	1	1	48	45	3	3	0	0	.21
Irregular menses	0	0	10	9	0	0	0	0	8	8	0	0	.32
Neutropenia	1	1	2	2	4	4	0	0	1	1	3	3	.37
Leukopenia	0	0	5	5	2	2	0	0	0	0	4	4	.39
Dyspnea	0	0	2	2	0	0	1	1	2	2	1	1	.41
Lymphopenia	0	0	3	3	0	0	0	0	5	5	0	0	.47
Nausea	2	2	3	3	0	0	2	2	1	1	0	0	.47
Infection	2	2	1	1	0	0	1	1	3	3	0	0	.57
Flatulence	46	43	0	0	0	0	31	29	13	12	0	0	.61
Abdominal pain	31	29	2	2	0	0	27	26	3	3	0	0	.62
Anemia	2	2	1	1	1	1	2	2	1	1	0	0	.70
Dyspepsia	5	5	2	2	0	0	6	6	2	2	0	0	.80
Diarrhea	29	28	1	1	0	0	28	27	1	1	0	0	.89
Fatigue	2	2	2	2	0	0	4	4	0	0	0	0	.98